Case Details

Year Initiated/Committed

2012

Year Resolved

2012

Settlement Amount

$3.45 million

Court

n/a

Docket Number

n/a
Print this Page

Lead State

AK, AR, AZ, CA, CO, CT, DC, DE, HI, IA, ID, IL, IN, LA, MD, MI, MN, MO, MS, MT, NC, NV, NY, OK, OR, SC, SD, TN, TX, UT, VA, VT, WA

Participating States

AK, AR, AZ, CA, CO, CT, DC, DE, HI, IA, ID, IL, IN, LA, MD, MI, MN, MO, MS, MT, NC, NV, NY, OK, OR, SC, SD, TN, TX, UT, VA, VT, WA

Defendant(s)

Ferring B.V.; Ferring Pharmaceuticals, Inc.; Aventis Pharmaceuticals, Inc.

Case Description

33 states investigated “pay for delay” allegations relating to DDAVP, a drug used to alleviate bed-wetting. States alleged that Aventis, holder of the patent for the medication, engaged in a scheme to delay the regulatory approval and sale of a generic version of DDAVP, in violation of state and federal antitrust law. States and defendants entered into a settlement under which states received $3.45 million, not as a civil penalty and defendants did not admit guilt.

Related Files

Back to Search